On eve of Alzheimer’s drug decision, Congress critiques FDA for Aduhelm review failures
By
Alicia Lasek
Jan 03, 2023
An “atypical review process and corporate greed” factored into the FDA’s approval of Alzheimer’s drug Aduhelm in 2021, congressional investigators say. They recommend sticking to protocol...
Nursing home providers help to design, refine facility IP program
By
Alicia Lasek
Apr 26, 2023
In partnership with providers, an infection control peer coaching program has been updated to improve its utility amid competing facility priorities and staffing shortages.
Depression drug eases Alzheimer’s agitation; new death in lecanemab trial raises concerns
By
Alicia Lasek
Nov 30, 2022
Two drugs in late-stage clinical trials are making news, one as a potential treatment for agitation, and the other for evidence of bleeding risk.
First appropriate use guidance published for Alzheimer’s drug Aduhelm
By
Alicia Lasek
Jul 28, 2021
The new guidelines cover how to choose appropriate patients, safely scale up to a full dose, monitor side effects and assess effectiveness. The authors also address when to stop therapy and what patients...
Cognitive skills decline with age, but the brain may compensate, study finds
By
Alicia Lasek
Sep 19, 2022
As it ages, the brain may attempt to make up for decline in some areas while it loses function elsewhere, investigators report.
Clinical briefs for Tuesday, March 1
By
Alicia Lasek
Mar 01, 2022
CMS wallops nursing homes with planned staffing requirements and increased penalties … FDA ups recommended dose of Evusheld monoclonal antibody treatment … Addressing residents’ kidney health an...
Clinical briefs for Friday, April 1
By
Alicia Lasek
Apr 01, 2022
HHS to award $110M in effort to expand HCBS … A nurse’s death raises the alarm about the profession’s mental health crisis … Internists push for Biden’s proposed budget to cover adult...
Clinical briefs for Monday, April 11
By
Alicia Lasek
Apr 11, 2022
Bridge temporary nurse aides to CNAs now, before waiver ends, AHCA warns … These “good faith” efforts count in revised vaccine mandate guidance … U.S. life expectancy falls for second year...
Feds halt an Eli Lilly antibody therapy in 3 states due to variant fears, while boosting the treatment...
By
Alicia Lasek
Mar 19, 2021
A COVID-19 variant circulating widely in California, Arizona and Nevada has rendered bamlanivimab alone ineffective, an FDA official reports. But Lilly says an approved alternative treatment “maintains...
Clinical briefs for Wednesday, July 5
By
Alicia Lasek
Jul 05, 2023
U.S. will allow drugmakers to discuss Medicare drug price negotiations … CIDRAP: CDC signs off on tweaks to flu vaccine recommendations … Healthcare groups fear SCOTUS affirmative action ruling will...